Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2013-01-14 | OcellO (The Netherlands) Merus (The Netherlands) | screening services to profile bispecific antibodies | collaboration |
Cancer - Oncology | Services contract | |
2013-01-14 | AstraZeneca (UK) Vanderbilt University (USA) | candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia | psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia | R&D licensing |
CNS diseases - Neurodegenerative diseases - Mental diseases - Psychiatric diseases | |
2013-01-14 | Boehringer Ingelheim (Germany) Horizon Discovery (UK) | Discovery Toolbox including isogenic models and phenotypic assays and genome editing technologies | undisclosed cancers |
R&D services |
Cancer - Oncology | |
2013-01-09 | Evotec (Germany) Yale University (USA) | novel exploratory drug targets and compounds | metabolic diseases, CNS diseases, immunological diseases, cancer, glioblastoma | R&D |
Metabolic diseases - CNS diseases - Immunological diseases - Cancer - Oncology | R&D agreement |
2013-01-08 | Priaxon (Germany) GSK (UK) | small molecule modulators of protein-protein-interactions | undisclosed | R&D |
undisclosed | R&D agreement |
2013-01-08 | to-BBB (The Netherlands) ALS Therapy Development Institute (USA) | CNS-targeted liposomal drug delivery system (G-Technology) | amyotrophic lateral sclerosis | R&D |
Neurodegenerative diseases - Neuromuscular diseases | R&D agreement |
2013-01-08 | Santaris Pharma (Denmark) miRagen Therapeutics (USA) | microRNA therapeutics (LNA drugs against up to six additional microRNA targets) | cardiovascular diseases | licensing |
Cardiovascular diseases | Licensing agreement |
2013-01-08 | Octoplus (The Netherlands) Sanofi (France) | services |
Services contract | |||
2013-01-08 | LFB, Laboratoire français du fractionnement des biotechnologies (France) Shin Poong (South Korea) | biotech medicinal products including ATryn® and FVIIa | joint-venture |
Hemtological diseases - Rare diseases | Joint-venture agreement | |
2013-01-08 | Hoopika Biotech (Austria) | nomination |
Cancer - Oncology - Infectious diseases | Nomination | ||
2013-01-08 | Hoopika Biotech (Austria) | nomination |
Cancer - Oncology - Infectious diseases | Nomination | ||
2013-01-07 | Evotec (Germany) MedImmune (USA - global biologics arm of AstraZeneca (UK) | beta cell regeneration assets and capabilities including EVT770 | diabetes | licensing |
Metabolic diseases | Licensing agreement |
2013-01-07 | Ethris (Germany) Shire (UK) | RNA-based therapeutics | monogenic genetic diseases | R&D |
Genetic diseases - Rare diseases | R&D agreement |
2013-01-07 | Qiagen (The Netherlands) Drug Response Dx (Germany) | companion diagnostic | rheumatoid arthritis | equity investment |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Licensing agreement |
2013-01-07 | Qiagen (The Netherlands) Insight Genetics (USA) | RET, ROS1 and DEPDC1 biomarkers | non-small cell lung cancer (NSCLC) | licensing |
Cancer - Oncology | Licensing agreement |
2013-01-07 | Qiagen (The Netherlands) Inserm Transfert (France) | biomarker for mutations of the HSP110 gene | colorectal cancer | licensing |
Cancer - Oncology | Licensing agreement |
2013-01-07 | Adaptimmune (UK) Life Technologies (USA) | intellectual property portfolio for methods of expanding and activating T cells transduced with engineered T cell receptors (TCR) | licensing |
Licensing agreement | ||
2013-01-07 | DebioPharm (Switzerland) Chugai (Japan) | FF284 (Debio 1347) and its companion diagnostic | development |
Cancer - Oncology | Development agreement | |
2013-01-07 | Ariad Pharmaceuticals (USA - MA) Newcastle University (UK) | ponatinib (Iclusig®) | chronic myeloid leukemia | clinical research |
Cancer - Oncology | Clinical research agreement |
2013-01-07 | Dako (Denmark) Eli Lilly (USA) | companion diagnostic tests for an investigational oncology medicine | undisclosed cancer | development |
Cancer - Oncology | Development agreement |